206650 — EuBiologics Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapHigh Flyer

Annual income statement for EuBiologics Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	R2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	28,490	39,385	55,467	69,366	96,035
Cost of Revenue
Gross Profit	6,927	15,261	23,613	34,019	55,953
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	31,411	47,323	60,080	83,573	70,281
Operating Profit	-2,921	-7,938	-4,614	-14,207	25,754
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-60,595	-30,820	-3,338	-14,615	18,457
Provision for Income Taxes
Net Income After Taxes	-60,134	-28,025	-3,437	-15,360	18,992
Minority Interest
Net Income Before Extraordinary Items
Net Income	-60,134	-27,574	-1,099	-13,879	19,117
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-60,134	-27,574	-1,099	-13,879	19,117
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-2,161	-765	-18.5	-19.8	672
Dividends per Share